These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25729794)

  • 1. [Is the waiver of chemotherapy for small, node-negative breast cancer justified? ].
    Sautter-Bihl ML; Sedlmayer F
    Strahlenther Onkol; 2015 Jan; 191(1):73-5. PubMed ID: 25729794
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    McArthur HL; Morris PG; Hudis CA
    J Clin Oncol; 2015 Jan; 33(1):124-5. PubMed ID: 25403210
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to H.L. McArthur et al.
    Vaz-Luis I; Lin NU
    J Clin Oncol; 2015 Jan; 33(1):125. PubMed ID: 25403214
    [No Abstract]   [Full Text] [Related]  

  • 4. How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.
    Reeder-Hayes KE; Carey LA
    J Clin Oncol; 2014 Jul; 32(20):2122-4. PubMed ID: 24888811
    [No Abstract]   [Full Text] [Related]  

  • 5. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to P.G. Gavin et al.
    Perez EA; Thompson EA; Ballman KV
    J Clin Oncol; 2015 Nov; 33(31):3672-3. PubMed ID: 26282664
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.
    Gavin PG; Song N; Kim SR; Pogue-Geile KL; Paik S
    J Clin Oncol; 2015 Nov; 33(31):3671-2. PubMed ID: 26282639
    [No Abstract]   [Full Text] [Related]  

  • 8. Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer?
    Foekens JA; Martens JW; Sleijfer S
    J Clin Oncol; 2015 Mar; 33(7):673-5. PubMed ID: 25605833
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
    Wolff AC; Hammond ME; Hayes DF
    J Natl Cancer Inst; 2012 Jun; 104(12):957-8. PubMed ID: 22581974
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.
    Hurvitz S
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):260-2. PubMed ID: 25003356
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual HER2 blockade slows metastatic breast cancer.
    Bender E
    Cancer Discov; 2012 Jan; 2(1):OF4. PubMed ID: 22585174
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab in neoadjuvant treatment for breast cancer.
    van der Veldt AA; Smit EF
    N Engl J Med; 2012 Apr; 366(17):1637; author reply 1638-40. PubMed ID: 22533581
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab in neoadjuvant treatment for breast cancer.
    Somlo G
    N Engl J Med; 2012 Apr; 366(17):1637-8; author reply 1638-40. PubMed ID: 22533582
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab in neoadjuvant treatment for breast cancer.
    Miklos GL
    N Engl J Med; 2012 Apr; 366(17):1638; author reply 1639-40. PubMed ID: 22533583
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of HER2-positive metastatic breast cancer.
    van Ramshorst MS; Sonke GS
    N Engl J Med; 2015 May; 372(20):1964. PubMed ID: 25970057
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of HER2-positive metastatic breast cancer.
    Swain SM; Clark E; Baselga J
    N Engl J Med; 2015 May; 372(20):1964-5. PubMed ID: 25970056
    [No Abstract]   [Full Text] [Related]  

  • 18. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant bevacizumab: positive data from a negative trial.
    Perez-Garcia J; Cortes J
    Lancet Oncol; 2013 Sep; 14(10):910-1. PubMed ID: 23932547
    [No Abstract]   [Full Text] [Related]  

  • 20. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.